Case Filesd-10-EFTA01465999Dept. of JusticeEFTA Document EFTA01465999
Unknown19p
Case File
sd-10-EFTA01465999Dept. of JusticeEFTA Document EFTA01465999
Other
Equity Research Healthcare I Biotechnology ARIAD Pharmaceuticals, Inc. Iclusig Comes Back With a New Label and REMS; Upgrade to Outperform and Increase Price Target to $12 On Friday, December 20, Ariad announced that it has reached agreement with the FDA for immediate reauthorization of Iclusig marketing in the United States, with a narrower label and accompanying Risk Mitigation Strategy (REMS) and postmarketing requirements (PMRs) Ariad plans to resume shipping of Iclusig by midJanu
Date
Unknown
Source
Dept. of Justice
Reference
sd-10-EFTA01465999
Pages
19
Persons
0
Integrity
Loading document viewer...
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,800+ persons in the Epstein files. 100% free, donor-supported, and independent. Donors see no ads.
Support This ProjectSupported by 1,550+ people worldwide
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.